Current News

Contact | Print version | Send article | RSS feed

Astex Grants Cytochrome P450 License to GlaxoSmithKline

26 Apr 2007 - Astex Therapeutics announced that it has granted a non-exclusive, worldwide license to its cytochrome P450 intellectual property to GlaxoSmithKline. Under the terms of the agreement, GlaxoSmithKline will pay an up-front fee to Astex in return for a license under Astex's portfolio of granted and pending cytochrome P450 patents. The specific financial terms and other details of the license were not disclosed.
 
"This agreement is another example of Astex's commitment to making its human cytochrome P450 technology available to other companies who could benefit or are already benefiting from its application in the discovery and development of novel drugs with reduced metabolic liabilities. We expect that the application of Astex's groundbreaking research, which was published in Nature and Science, will benefit many companies' drug discovery and development programmes", said Leon Bushara, Chief Executive Officer.